Suppr超能文献

胶质母细胞瘤患者肿瘤体积的预后价值:即使不完全切除,肿瘤大小对患者也很重要。

Prognostic Value of Tumor Volume in Glioblastoma Patients: Size Also Matters for Patients with Incomplete Resection.

机构信息

Department of Neuroradiology, Klinikum rechts der Isar der Technischen Universitat, Munich, Germany.

Department of Neurosurgery, Klinikum rechts der Isar der Technischen Universitat, Munich, Germany.

出版信息

Ann Surg Oncol. 2018 Feb;25(2):558-564. doi: 10.1245/s10434-017-6253-0. Epub 2017 Nov 20.

Abstract

BACKGROUND

Incomplete resection of glioblastoma is discussed controversially in the era of combined radiochemotherapy.

OBJECTIVE

The aim of this study was to analyze the benefit of subtotal tumor resection for glioblastoma patients as this was recently questioned in the era of radiochemotherapy.

METHODS

Overall, 209 patients undergoing surgery for newly diagnosed WHO grade IV gliomas were retrospectively analyzed, and pre- and postoperative tumor volumes were manually segmented (cm). Survival analyses were performed, including prognostic factors such as age, Karnofsky performance score (KPS), O-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status, and adjuvant treatment regimen.

RESULTS

Pre- and postoperative tumor volume is significantly associated with pre- and postoperative KPS, as well as age (p < 0.001). Postoperative tumor volume remained a significant prognostic factor in a multivariate analysis, independent of other prognostic factors (hazard ratio 1.0365, 95% confidence interval 1.0235-1.0497, p < 0.001).

CONCLUSIONS

In the era of molecularly-driven radiochemotherapy, glioblastoma surgery remains a major prognostic factor. Even in situations in which a gross total resection cannot be achieved, maximum safe reduction of tumor burden should be attempted.

摘要

背景

在放化疗联合治疗的时代,关于胶质母细胞瘤的不完全切除存在争议。

目的

本研究旨在分析次全切除肿瘤对胶质母细胞瘤患者的益处,因为在放化疗时代,这一问题最近受到了质疑。

方法

回顾性分析了 209 例新诊断为 IV 级 WHO 胶质瘤患者的手术资料,手动分割术前和术后肿瘤体积(cm)。进行了生存分析,包括年龄、卡氏功能状态评分(KPS)、O-甲基鸟嘌呤-DNA-甲基转移酶(MGMT)启动子甲基化状态和辅助治疗方案等预后因素。

结果

术前和术后肿瘤体积与术前和术后 KPS 以及年龄显著相关(p<0.001)。在多因素分析中,术后肿瘤体积仍然是一个显著的预后因素,独立于其他预后因素(危险比 1.0365,95%置信区间 1.0235-1.0497,p<0.001)。

结论

在分子驱动的放化疗时代,胶质母细胞瘤手术仍然是一个主要的预后因素。即使在无法实现完全切除的情况下,也应尝试最大限度地安全减少肿瘤负担。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验